The company has also announced BBI Group as manufacturer for the test it is creating with Cytiva.
The Waterbeach-based gene editing company says it is encouraged by its prospects for the rest of 2020.
They will also prepare for future pandemics.
The combined company will be headquartered at Babraham Research Campus and in Cambridge, Massachusetts.
The Cambridge-based biopharmaceutical company recorded revenue and profit growth despite the Covid-19 pandemic.
Move will give the Whittlesford-based company access to patient samples.
The group expects to report revenues of £260million and is in the midst of a growth strategy.
The deal surrounds antibody drug conjugate DS-1062, which could redefine treatments in lung, breast and multiple other cancers.
AZD1222 generates both an antibody and T cell response, and appears safe, data shows.
The human synthetic biology pioneer joins PetMedix, Mission Therapeutics and RxCelerate at the site.
